Korean Drug고려제약
014570 · KOSDAQ · ₩014570 · 고려제약
₩2,845▲ ₩25 (0.89%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩63B | ₩73B | ₩81B | ₩80B | ₩74B |
| Cost of sales | ₩36B | ₩39B | ₩44B | ₩45B | ₩43B |
| Gross profit | ₩27B | ₩34B | ₩37B | ₩35B | ₩31B |
| Operating income | ₩6.9B | ₩9.1B | ₩18B | ₩14B | ₩11B |
| Net income | ₩6.5B | ₩3B | −₩4.9B | ₩12B | ₩9B |
| Net income to shareholders | ₩6.5B | ₩3B | −₩4.9B | ₩12B | ₩9B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩94B | ₩89B | ₩90B | ₩95B | ₩89B |
| Current assets | ₩69B | ₩63B | ₩63B | ₩73B | ₩70B |
| Cash and equivalents | ₩4.9B | ₩4.1B | ₩12B | ₩3.4B | ₩4.8B |
| Total liabilities | ₩11B | ₩11B | ₩13B | ₩9.8B | ₩12B |
| Current liabilities | ₩8.3B | ₩7.2B | ₩9.9B | ₩7.4B | ₩10B |
| Total equity | ₩83B | ₩78B | ₩77B | ₩85B | ₩77B |
| Shareholders' equity | ₩83B | ₩78B | ₩77B | ₩85B | ₩77B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩13B | ₩4.9B | −₩2B | ₩5.9B | ₩8.8B |
| Capital spending | ₩457M | ₩1B | ₩5.8B | ₩6.1B | ₩1.1B |
| Free cash flow | ₩13B | ₩3.8B | −₩7.8B | −₩180M | ₩7.7B |
| Dividends paid | ₩1.7B | ₩1.6B | ₩1.9B | ₩1.8B | ₩1.6B |
Consolidated where available. Amounts in won.
Also known as: Korean Drug / 고려제약 / 014570 / KRX:014570
Source: KRX statistical information